From the screening of clinical MPN samples with the custom NGS panel, 21 unique variants including MPN driver mutations in JAK2 and CALR, and one pathogenic stopgain variant in TET2 with a VAF of 1.4% were identified. This evidence concerns the gene CALR and myeloproliferative neoplasm.